Skip to main content

Neupogen News

FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen

July 01, 2024 Tanvex BioPharma, Inc. (TWSE: 6541) announced that The U.S. Food and Drug Administration (FDA) had completed their review of our submission of Nypozi (TX01) and approved the biologics...

FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen

PISCATAWAY, N.J.--(BUSINESS WIRE)-- March 2, 2022 Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for...

FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen

July 20, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen1...

FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)

March 6, 2015 – The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Neutropenia Associated with Chemotherapy

Neupogen patient information at Drugs.com